Avoid self-medication with ibuprofen against COVID-19 symptoms: WHO

Image
AFP Geneva
Last Updated : Mar 17 2020 | 6:40 PM IST

The World Health Organisation on Tuesday recommended that people suffering from COVID-19-like symptoms should avoid self-medicating with ibuprofen, after French authorities warned anti-inflammatory drugs could worsen the effects of the virus.

The warnings over the weekend by French Health Minister Olivier Veran followed a recent study in The Lancet weekly medical journal that hypothesised that an enzyme that is boosted when taking anti-inflammatory drugs like ibuprofen could facilitate and worsen COVID-19 infections.

Asked about the study, WHO spokesman Christian Lindmeier told reporters in Geneva that the UN health agency's experts were "looking into this to give further guidance".

"In the meantime, we recommend using rather paracetamol, and do not use ibuprofen as a self-medication. That's important," he said.

He stressed though that if ibuprofen had been "prescribed by the healthcare professionals, then, of course, that's up to them".

His comments came after Veran sent a tweet cautioning that the use of ibuprofen and similar anti-inflammatory drugs could be "an aggravating factor" in COVID-19 infections.

"In the case of fever, take paracetamol," he wrote.

He stressed that patients already being treated with anti-inflammatory drugs, should "ask advice from your doctor." Paracetamol must be taken strictly according to the dose, because too high a dosage can be very dangerous for the liver.

The COVID-19 pandemic, which has infected more than 180,000 people worldwide and killed more than 7,000, causes mild symptoms in most people, but can result in pneumonia and in some cases severe illness that can lead to multiple organ failure.

Even before the pandemic, French authorities last year sounded the alarm over serious "infectious complications" linked to the use of ibuprofen, which is sold under various brands like Nurofen and Advil, and other anti-inflammatory drugs.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 17 2020 | 6:40 PM IST

Next Story